Lenabdor

Lenalidomide, the active ingredient in Lenabdor, is a Immunomodulatory drug (IMiD) presented as an oral formulation for oral use. It is used to treat certain blood cancers, including multiple myeloma and myelodysplastic syndromes, in adult patients.

GNH USA supplies Lenabdor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is an immunomodulatory agent indicated for specific hematologic malignancies.

Multiple myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. Myelodysplastic syndromes: reduces transfusion dependence and delays transformation to acute leukemia in patients with lower‑risk disease.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: persistent tiredness affecting daily activities. - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools that may lead to dehydration. - Rash: skin irritation or mild eruptions.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia or thrombocytopenia: markedly low blood cell counts. - Secondary primary malignancies: emergence of new cancers. - Hepatic toxicity: elevated liver enzymes or liver injury. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should assess patient suitability and monitor for potential risks.

Monitor blood counts: perform regular complete blood count tests to detect cytopenias. Assess pregnancy risk: ensure effective contraception and avoid use in pregnancy. Evaluate renal function: adjust therapy based on kidney performance. Avoid teratogenic drugs: do not co‑administer with agents known to cause birth defects. Counsel on contraception: advise both male and female patients on reliable birth control methods. Store at ambient temperature: keep in the original container, protect from moisture and light.

Lenalidomide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide exposure. - Potent CYP3A4 inducers (e.g., rifampin): may reduce therapeutic levels. - Anticoagulants (e.g., warfarin): heightened risk of bleeding.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate renal impairment. - CYP2C19 inhibitors (e.g., fluconazole): modest increase in plasma concentration. - Live vaccines: reduced vaccine efficacy and potential infection risk.